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Purpose: The formulation of topical ophthalmic products with appropriate therapeutic effect 
and patient compliance is a major challenge. To increase the efficiency of the ocular delivery of 
the drug, the enhancement of water solubility and the contact time of the drug on the surface of 
the cornea are necessary. In this work, prednisolone (PR)-containing eye drops were formulated 
with antimicrobial, mucoadhesive biopolymer and PR–cyclodextrin inclusion complex. This 
approach can be used for the development of innovative ophthalmic formulations.
Materials and methods: After adjusting the optimal physiological parameters, the amount 
of the required cyclodextrin for the highest penetration of PR was determined by dialysis mem-
brane diffusion study. The viscosity, surface tension and mucoadhesion of the eye drops were 
measured. The microbiological effectiveness of zinc-hyaluronate (ZnHA) was investigated by 
a standard method of the European Pharmacopoeia.
Results: In this case, no significant difference of surface tension was measured in products 
with different amounts of cyclodextrin. According to the results of the tensile test, ZnHA as 
a mucoadhesive biopolymer improves the mucoadhesion of ophthalmic products. The anti-
microbial stability of formulations preserved by ZnHA meets requirement B of the European 
Pharmacopoeia.
Conclusion: It can be stated that the innovative PR-containing compositions are suitable for 
producing mucoadhesive, properly preserved aqueous ophthalmic solutions with increased 
bioavailability attributes.
Keywords: pharmaceutical formulation, zinc-hyaluronate, ocular drug delivery, microbiological 
stability, membrane diffusion
Introduction
Topical ocular drug delivery is restricted by barriers, such as eye blinking and lachrymal 
secretion, which result in low bioavailability after application. Solving this problem 
is a major challenge in the field of research and development and necessary because 
topically applied formulations have the highest patient adherence in the treatment of 
eye diseases.1
In order to reach an optimal efficiency, the transcorneal penetration of the drug 
is important. The cornea is composed of five layers: the lipophilic epithelium, the 
hydrophilic stroma between Descemet’s membrane and Bowman’s layer, and the 
lipophilic endothelium. To complete the optimal transcorneal penetration, a balance 
in the hydrophilicity and lipophilicity of the drug and the vehicle is needed. The con-
tinuous secretion of tear fluid rapidly dilutes and washes out the applied eye drop and 
limits the contact time of drugs on the eye surface.2
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In ophthalmic surgery, glucocorticoid derivatives like 
prednisolone (PR), dexamethasone and fluorometholone 
are widely used for postoperative inflammation prophylaxis. 
Due to their low aqueous solubility, they are present on the 
market primarily in suspension formulations. When there is 
a risk of severe inflammation, especially after cornea trans-
plantation, anti-inflammatory steroid therapy is needed by 
giving a subconjunctival or subretinal injection.2,3 Instead of 
these complicated and uncomfortable invasive applications, 
it would be more acceptable to use noninvasive, topical, 
water-soluble corticosteroid-containing eye drop formula-
tions with higher efficiency.
One of the ways to increase efficiency on the eye sur-
face is to solubilize the active pharmaceutical ingredient 
(API) in aqueous system, thereby ensuring that the optimal 
concentration of the drug appears near the epithelium of the 
cornea. Cyclodextrins (CDs) can solubilize lipophilic, water-
insoluble drugs with suitable molecular size and structure, 
so they can be formulated in aqueous solutions. These cyclic 
oligosaccharides consist of α-(1,4) linked α-d-glucopyranose 
units. As a result of the lipophilic cavity of CD, an inclusion 
complex forms with the lipophilic drug molecules, due to 
thermodynamic interactions.4–7 This complex is soluble in 
water because of the hydrophilic external surface of CD 
and can be dissociated in the aqueous tear fluid. As a result, 
equilibrium is achieved between the complexed and non-
complexed components. The determination of the optimal 
concentration of CD is important. With the proper amount 
of CD, the API can be in aqueous solution permanently, so 
a sufficient amount of drug molecules appears at the surface 
of the cornea, which induces the increase of drug permeation. 
If the concentration of CD is too low, it is not able to bring 
about the required water solubility of the drug, whereas too 
much CD decreases the amount of free, permeable drug mol-
ecules at the cornea.8 The cytotoxicity of β-CD derivatives 
was investigated by several research groups on different cell 
lines. In ophthalmology, the hydroxypropyl derivatives of 
β- and γ-CDs, the randomly methylated β-CD and sulfobutyl-
ether-β-cyclodextrin are tolerated because of the preferential 
cytotoxic properties against cornea epithelial cells.4,9,10 Now, 
licensed CD-containing products are widely used in medical 
practice.5,6
The reflex mechanisms of the eye, such as blinking and 
lachrymal secretion, result in rapid drug elimination from 
the surface. To maintain the optimal, therapeutic drug level, 
more frequent application is needed, which can induce many 
side effects and decrease patient compliance. This problem 
can be solved by increasing the contact time of API on the 
surface of the cornea by increasing the viscosity with inserts, 
microspheres or mucoadhesive polymers. With longer 
residence, the penetration rate of API can be increased.11 
At a needlessly high viscosity level, the reflex mechanisms 
of the eye, blinking and lachrymation, are induced until 
the physiological viscosity of the tear is regained. Some 
viscosity increasing compounds have a mucoadhesive effect. 
With these materials optimal residual time can be achieved, 
without increasing viscosity to an unnecessarily high level. 
The mechanism of mucoadhesion involves tight contact and 
interpenetration between the mucoadhesive component and 
the proteoglycan chains of the mucin. Bioavailability can 
be improved through this mechanism.12,13 Hyaluronic acid 
is a linear anionic polysaccharide, a main component in the 
extracellular matrix of connective tissue. This biocompatible 
polymer can aid tissue manipulation and protect the corneal 
endothelium due to its proliferative effect. It interacts with 
mucin covering the conjunctival and corneal surfaces of the 
eye, and as a result ocular mucoadhesion is achieved.14–16
Benzalkonium chloride (BK) is a cationic surfactant 
additive, which is widely used as a microbiological pre-
servative agent in eye drop formulations. BK may destroy 
the cell membrane of microorganisms, which results in an 
antimicrobial effect. Toxicity for corneal and conjunctival 
epithelial cells and incompatibility with contact lenses were 
reported earlier.17–19 BK causes DNA single- and double-
strand breaks in corneal epithelial cells, so the barrier of the 
eye surface may be damaged. Allergic reaction, eye irritation 
and increased tear secretion may be caused by application.17–19 
It is also known that resistance of Pseudomonas aeruginosa 
against BK appears due to decreasing the permeation 
through the cell wall.20 The antimicrobial properties of Zn2+ 
ion-containing compounds are favorable in pharmaceutical 
formulations. Marketed products, like Ophylosa® (Gedeon 
Richter Plc, Budapest, Hungary) contain zinc-hyaluronate 
(ZnHA) and zinc-gluconate (ZnGlu) for replacing BK. The 
antimicrobial effect depends on the reactive oxygen species 
generating mechanism, the cell wall destabilizing effect of 
cytotoxic, dissolved Zn2+ ion in a water-based environment.21 
Zinc-containing polymers like ZnHA could be acceptable, 
combined with a zinc salt of gluconic acid, ZnGlu, to reach 
the suitable antimicrobial stability. Further investigation 
is needed to confirm the capability of these compounds as 
replacements of the unfavorable BK. ZnHA could be a useful 
antimicrobial and mucoadhesive additive in ophthalmic 
formulations.22
The aim of this study was to develop an innovative, 
water-soluble PR-containing eye drop formulation with 
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infrequent application, adequate microbiological stability and 
acceptable physiological (surface tension, pH, osmolality), 
rheological and mucoadhesive parameters using a CD 
inclusion complex, and preservative, mucoadhesive ZnHA 
and ZnGlu.
Material and methods
Materials
PR was purchased from Henan Lihua Pharmaceutical 
Company (Henan, China). Hydroxypropyl-β-cyclodextrin 
(HPBCD) was obtained from Wacker-Chemie GmbH 
(Munich, Germany), hydroxypropyl-γ-cyclodextrin (HPGCD) 
was kindly donated by Cyclolab Ltd. (Budapest, Hungary), 
ZnHA and ZnGlu from Gedeon Richter Plc (Budapest, 
Hungary). BK, sodium chloride (NaCl), boric acid and borax 
(for borate buffer) were obtained from Molar Chemical 
Ltd. (Halásztelek, Hungary). Mucin (porcine gastric mucin 
type II) was purchased from Sigma-Aldrich (St Louis, MO, 
USA). Lachrymal fluid of pH=7.4 was prepared by dissolving 
2.2 g L−1 NaHCO
3
, 6.26 g L−1 NaCl, 1.79 g L−1 KCl, 96.4 mg 
L−1 MgCl
2
⋅6H
2
O and 73.5 mg L−1 CaCl
2
⋅H
2
O in distilled 
water, the pH being adjusted with 1 M HCl.23
Methods
Phase solubility test
The phase solubility of PR was measured by adding it 
in excess amount to HPBCD- and HPGCD-containing 
solutions (purified water was used as a solvent) with dif-
ferent concentrations (0–150 mM) and allowing it to be 
intermixed for 48 hours. Thereafter, the solutions were fil-
tered with a 0.45 µm membrane filter (Millex-HV Syringe 
Driven Filter Unit, 0.45 µm, EMD Millipore, Billerica, 
MA, USA) and analyzed with UV spectrophotometry 
(wavelength: 248 nm, Unicam UV/Vis Spectrometer, ATI 
Unicam, Cambridge, UK).
The type of diagrams and the ratio of complexes were 
determined and the stability constants of complexes (K
s
) 
were calculated by Equation (1):24,25
 Ks = Slope/{Intercept (1–Slope)} (1)
Preparation of products
The eye drops in the market contain 1% or 0.12% PR-acetate 
in suspension formulations. According to these products, we 
use 0.1% PR as API. Considering the probable improvement 
of the bioavailability, this amount is suitable and proper 
therapeutic effect can be expected. Defined amounts of 
HPGCD or HPBCD was dissolved in borate buffer and 0.5% 
ZnHA–ZnGlu-containing aqueous solutions. According to 
Horvát et al, this amount of ZnHA could not create a vis-
cous, gel-formulation, therefore the unfavorable attributes 
of high viscosity are not expected.26 PR was dissolved in 
these solutions. Products were put into an ultrasonic bath 
for 10 minutes. Osmolality was set with NaCl to about 
300 mOsm kg−1; the pH was about 6.20 in every product. 
Every eye drop was prepared in aseptic environment.
study of diffusion through dialysis membrane
The penetration of API depends on the concentration of CD. 
Overly high or low amounts of CD can cause a decreased 
absorption of API, therefore its determination is important. 
With the investigation of the diffusion of PR through a 
dialysis membrane, the optimal CD quantity as a function 
of drug penetration can be adjusted.
The amount of CD for the optimal penetration of API 
was determined by drug diffusion monitoring. Zellutrans/
Roth cellulose dialysis membrane tube (10 mm wide, 
6.4 mm diameter, MWCO: 12,000–14,000 D) was used for 
the experiment. The membrane pouches were closed with 
Spectra/Por Closures. The sample (2.00 mL) was injected 
into the pouches and put into 25 mL of borate buffer-
containing aqueous acceptor phase (pH=7.4) tempered at 
35°C. At various time intervals (15, 30, 60, 120, 180, and 
240 minutes), 1.00 mL of the sample was removed from the 
acceptor phase and refilled with the buffered solution. The 
length of the measurement is reasonable, due to the possible 
increased retention on the surface of the eye. Four samples 
were measured parallel at the same time. The PR content 
was analyzed with UV spectrophotometry.
Viscosity
A Physica MCR 101 rheometer with cone-plate measur-
ing device (Anton Paar, Graz, Austria, CP25-1, cone angle 
0.997°, 25 mm diameter) was used for the measurement. 
The formulations were investigated at 25°C; the shear rate 
was increased from 0.1 s−1 to 100 s−1, the means of the data 
at 100 s−1 shear rate were calculated at the evaluation. The 
viscosity values were illustrated as a function of the concen-
tration of CD derivatives.
surface tension
The surface tension of the samples was measured with OCA 
20 contact angle system (Dataphysics Instruments GmbH, 
Filderstadt, Germany) by analyzing the shape of pendant drop. 
The values of surface tension were determined with SCA 
20/22 software module using the Young-Laplace equation.27
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Efficacy of antimicrobial preservation
The applicability of ZnHA–ZnGlu as ophthalmic preserva-
tive system was investigated vs BK, because the other compo-
nents in the formulation could affect its antimicrobial effect. 
The antimicrobial effectiveness of the ophthalmic samples 
was determined according to the standards of the European 
Pharmacopoeia (EP). ZnHA–ZnGlu and BK as preservatives 
were tested on control strains, Staphylococcus aureus (ATCC 
6538), P. aeruginosa (ATCC 9027) and Candida albicans 
(ATCC 10231). Inoculum suspensions of the microorganisms 
were prepared by using a sterile suspending fluid containing 
9 gL−1 NaCl. The number of colony-forming units (CFU) was 
determined with plate count. The microbial count was about 
108 CFU per milliliter. Preserved samples were inoculated 
with the suspensions of bacteria and fungus by adding 106 
CFU per milliliter. The volume of the inoculated suspensions 
of microorganisms did not exceed 1% of the volume of the 
product. According to the standard method, three parallel 
samples were removed at zero hours and at appropriate 
intervals (6 hours, 24 hours, 7 d, 14 d, 28 d), and plated to 
Sabouraud-dextrose fluid agar (fungus) or tryptic soy fluid 
agar (bacteria). Bacteria-containing samples were incubated 
at 30°C–35°C for 24 hours and fungus-containing samples 
at 20°C–25°C for 48 hours. The reduction of these values 
was converted to log
10
 and compared with requirements A 
and B of the EP (EP-A, EP-B). The requirement of preserva-
tive is determined by the EP as the logarithmic reduction of 
CFU. The effectiveness needed against bacteria and fungus 
is managed separately. The decrease of CFU needs to be in 
accordance with the EP-A criteria. In cases when adverse 
drug reaction can appear with the A criteria, the EP-B crite-
ria are acceptable.28 The aim was to determine whether the 
preservative effect of ZnHA meets the requirements of EP 
in the presence of CD derivatives.
Mucoadhesion
The mucoadhesion of CD-containing eye drops was deter-
mined by the tensile test method, based on the measurement 
of the forces of detachment and the total work of adhesion 
needed to separate the surfaces, resulting from the area 
under the force–distance curve.29,30 Samples contained two 
types of CDs (HPBCD and HPGCD) prepared with and 
without ZnHA–ZnGlu. The purpose was to determine the 
effect of ZnHA on mucoadhesion and to establish if the 
presence of the type of CD has an effect in mucoadhesion. 
The measurement was performed with a TA.XT Plus Texture 
analyzer (ENCO, Spinea, Italy) instrument equipped with a 
1 kg load cell and a cylinder probe with a diameter of 1 cm. 
The sample (20 µL) was attached to the cylinder probe and 
placed in contact with a filter paper disc wetted with 50 µL 
of an 8% w/w mucin dispersion or simulated lachrymal 
fluid (blank, pH=7.4). The mucin dispersion was made with 
simulated lachrymal fluid.26,31
A 2,500 mN preload was used for 3 minutes. The cylinder 
probe was moved upward to separate the sample from the 
substrate at a prefixed speed of 2.5 mm min−1.
statistical analysis
One-way and two-way analysis of variances were used to 
compare the mean values. Statistical analysis was performed 
by GraphPad Prism five statistical software (GraphPad Soft-
ware, Inc., La Jolla, CA, USA). The level of significance 
was set to P,0.05.
Results and discussion
Phase solubility test
The phase solubility of PR in HPBCD- and HPGCD-containing 
aqueous solutions (0–150 mM) is shown in Figure 1.
The solubility of PR was increased linearly by increas-
ing the concentration of HPBCD or HPGCD. The diagrams 
are Higuchi A
L
 type for both CDs, therefore the formation 
of 1:1 complexes can be assumed. In case of HPBCD, the 
apparent stability constant of the complex is 1,286.4 M−1, 
and the constant of the PR–HPGCD complex was measured 
to be 1,778.5 M−1.
It is stated that PR has greater affinity for complex- 
formation with HPGCD. With the equation of regression 
lines, the concentration of CD needed to solubilize the 
required amount of API can be determined. These calcu-
lated concentrations are the centers of intervals that were 
used in the drug diffusion study in case of both types of CD 
derivatives.
study of diffusion through dialysis 
membrane
Eye drops with or without mucoadhesive polymer were for-
mulated and examined. The concentrations of CD derivatives 
for the penetration of PR were optimized. The penetrated 
PR as a function of the concentration of CD is shown in 
Figure 2.
The results show that 4 mM HPGCD and 5 mM HPBCD 
induce the highest diffusion of PR through the dialysis 
membrane. Under the optimal CD concentration a part of 
free, hydrophobic drug remained in the pouches. Above the 
optimal CD level, the excess amount of CD keep the free PR 
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in complex, therefore less amount of free API is detectable 
in the acceptor phase.
Thereafter, mucoadhesive ZnHA–ZnGlu additives 
were added to the eye drops, which ensure antimicrobial, 
preservative effect in the formulations. It was found that 
the application of biopolymer has no effect on the diffusion 
of PR. The same amount of drug penetrated through the 
dialysis membrane at each period in case of both composi-
tions (Figure 3).
Viscosity
The viscosity of ZnHA and PR-CD complex-containing 
ophthalmic formulations was measured. The results are 
shown in Table 1.
According to previous reports, the viscosity should be 
under 30 mPa s.32,33 Above this level, blurred vision and 
discomfort appear, which result in faster elimination due 
to reflex mechanisms of the eye. The results show that the 
viscosity of our formulations is appropriate in the range of 
9.2–24.2 mPa s.
surface tension
The surface tension of normal tear is about 43 mN m−1.34 
It is not optimal if the surface tension of products is much 
higher than that of the lacrimal fluids because it has an impact 
on the therapeutic effect of pharmaceutics applied on the 
eye, through affecting the spreading of the eye drops on the 
ocular surface, although no regular critical parameter was 
found for the surface tension of eye drops in the EP. The 
surface tension of formulations preserved with ZnHA was 
measured by using an OCA 20 contact angle system. The 
results are shown in Table 2.
No significant difference was found between the values. 
The surface tensions of the eye drops are about 60 mN m−1, 
Figure 1 Phase solubility diagrams of Pr in aqueous hPBcD () and hPgcD () solutions at 25°c.
Abbreviations: cD, cyclodextrin; hPBcD, hydroxypropyl-β-cyclodextrin; hPgcD, hydroxypropyl-γ-cyclodextrin; Pr, prednisolone.
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Figure 2 Pr diffusion through dialysis membrane as a function of the concentration of hPgcD and hPBcD after 240 minutes.
Abbreviations: hPBcD, hydroxypropyl-β-cyclodextrin; hPgcD, hydroxypropyl-γ-cyclodextrin; Pr, prednisolone.
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which is higher than the surface tension of lacrimal fluid. 
Ophthalmic products were investigated by Han et al, 
and the range of the surface tension values was between 
34.3 mN m−1 and 70.9 mN m−1.35–37 According to this study, 
the surface tension of formulations meets the requirements 
for ophthalmic products.
Efficacy of antimicrobial preservation
In Samples I (with HPBCD) and II (with HPGCD), ZnHA–
ZnGlu were used as preservative compounds. The results 
are shown in Table 3.
The logarithmic decrease of S. aureus was 1.5 after 6 
hours, 2 after 24 hours, and no bacteria were detected in the 
samples after 7 days. In case of P. aeruginosa, the logarithmic 
decrease is higher at the earlier period, but the bacterium 
appeared in every sample. The logarithmic decrease of 
C. albicans was 1 after 6 hours, and no fungi were detected 
later. In summary, the preservative effect of ZnHA–ZnGlu-
containing samples meets the EP-B criteria. The antimicrobial 
effectiveness of ZnHA–ZnGlu is lower against P. aeruginosa 
compared with the other microorganisms.
The microbiological stability of Samples III (with 
HPBCD) and IV (with HPGCD), which contained BK as a 
preservative agent, was tested (Table 4).
The logarithmic decrease of S. aureus was 1 after 6 hours, 
2 after 24 hours, and no bacteria were detected later in Sample 
III. For P. aeruginosa the logarithmic decrease was two 
and no change was detected later. In C. albicans-containing 
samples, no fungi were found after 7 days. In Sample IV, 
for S. aureus and C. albicans, the number of CFU was zero 
after 6 hours. In case of P. aeruginosa, the antimicrobial 
effect was lower due to the known resistance of the bacterium 
against BK. The microbiological stability of Samples III 
and IV meets the requirements of the EP. In Sample III, the 
Figure 3 effect of Znha–Znglu on the diffusion of Pr through dialysis membrane (light column: with Znha–Znglu; dark column: without Znha–Znglu).
Abbreviations: Pr, prednisolone; Znglu, zinc-gluconate; Znha, zinc-hyaluronate.
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Table 1 Viscosity values of Znha-Pr-hPgcD (i)- and Znha-
Pr-hPBcD (ii)-containing products
Concentration 
of CD (mM)
Viscosity 
(mPa s)
SD
i 3 22.8 4.5
4 9.2 3.3
5 19.7 1.2
ii 3 24.2 3.4
4 18.4 2.8
5 18.1 0.7
6 22.1 3.7
Abbreviations: cD, cyclodextrin; hPBcD, hydroxypropyl-β-cyclodextrin; 
hPgcD, hydroxypropyl-γ-cyclodextrin; Pr, prednisolone; Znha, zinc-hyaluronate.
Table 2 surface tension of Znha-Pr-hPgcD (i)- and Znha-
Pr-hPBcD (ii)-containing formulations
Concentration 
of CD (mM)
Surface tension 
(mNm-1)
SD
i 3 61.12 0.24
4 61.65 0.31
5 61.20 0.24
ii 3 59.31 0.15
4 59.46 0.23
5 58.65 0.22
6 59.06 0.37
Abbreviations: cD, cyclodextrin; hPBcD, hydroxypropyl-β-cyclodextrin; 
hPgcD, hydroxypropyl-γ-cyclodextrin; Pr, prednisolone; Znha, zinc-hyaluronate.
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antimicrobial effect of BK is lower than in Sample IV. It can 
be assumed that there is a competition between PR and BK 
for the cavity of HPBCD, so the preservative effect of BK is 
decreased by the inclusion complex formation.38
According to the EP-B criteria, 0.5% ZnHA–ZnGlu 
compounds ensure the proper microbiological stability of eye 
drop formulations. In case of P. aeruginosa, the antimicrobial 
effect of the ZnHA–ZnGlu system is higher than the effect 
of BK. Considering these results with the irritative attribute 
of BK, application of ZnHA–ZnGlu as a preservative can be 
favorable in ophthalmic products.
Mucoadhesion
The measured adhesive force values are shown in Figure 4. 
Lachrymal fluid was used as blank.
There is a large difference in the measured force between 
the blank and the mucin dispersion. All the samples show 
mucoadhesivity; samples prepared with ZnHA have signifi-
cantly higher values than samples prepared without it. This 
proves the importance of the presence of ZnHA because the 
interpenetration between the ZnHA chains and mucin can 
be assumed. These samples can have better mucoadhesive 
properties and cause decreased administration frequency and 
a lower active ingredient concentration.
The type of CD does not play an important role in 
mucoadhesion because there is no significant difference 
between the samples prepared with HPBCD and HPGCD. 
According to the results, it can be established that ZnHA 
plays an important role in mucoadhesion.
Conclusion
To increase the bioavailability of steroid-containing ophthal-
mic products is a great challenge. Over the years, there have 
been numerous attempts to enhance the efficacy of eye drops. 
Our aim was to formulate PR-containing aqueous solutions 
by CD inclusion complex and to create mucoadhesive eye 
drops using antimicrobial ZnHA and ZnGlu, with suitable 
physiological parameters.
Aqueous solutions of PR were formulated by inclusion 
complexation with HPBCD and HPGCD. The investiga-
tion of the diffusion of PR through the dialysis membrane 
revealed that 5 mM of HPBCD, and 4 mM of HPGCD 
caused the highest penetration of API in in vitro circum-
stances. The addition of ZnHA and ZnGlu had no effect on 
the penetration properties. The measurement of viscosity 
showed that the 5-mM HPBCD- and 4-mM HPGCD-con-
taining products had the lowest viscosity values, meeting 
the requirements of the EP. It was found that the concentra-
tion of CDs has no effect on the surface tension of the eye 
drops, and these values are optimal compared with previ-
ously investigated ophthalmic products. The mucoadhesive 
properties of ZnHA-containing formulations were proved 
with the tensile test, resulting in a higher retention time of 
the eye drop on the surface. The type of CD derivative has 
no influence on mucoadhesivity. During the preservative 
effectiveness test, it was proven that the ZnHA–ZnGlu 
combination is applicable as an antimicrobial, preserva-
tive compound. The microbiological stability of ZnHA-
containing products meets the requirements of the EP in 
case of S. aureus, P. aeruginosa and C. albicans. It can 
be stated that BK with unfavorable toxicity properties for 
the corneal epithelial cells can be replaced with the more 
biocompatible ZnHA.
Table 3 Preservative effectiveness against Staphylococcus aureus, 
Pseudomonas aeruginosa and Candida albicans in samples i and ii
Microbial log reduction
6 hours 24 hours 7 days 14 days 28 days
S. aureus
sample i 1.5 2 nd nd nd
sample ii 1.5 2 nd nd nd
criteria (B) – 1 3 – ni
P. aeruginosa
sample i 2 3 – 4 –
sample ii 2 – 3 4 –
criteria (B) – 1 3 – ni
C. albicans
sample i 1.5 – – – nd
sample ii 1 – – – nd
criteria (B) – – – 1 ni
Abbreviations: nd, not detectable; ni, no increase.
Table 4 Preservative effectiveness in samples iii and iV against 
Staphylococcus aureus, Pseudomonas aeruginosa and Candida albicans
Microbial log reduction
6 hours 24 hours 7 days 14 days 28 days
S. aureus
sample iii 1 2 nd nd nd
sample iV nd nd nd nd nd
criteria (B) – 1 3 – ni
P. aeruginosa
sample iii 2 – – – –
sample iV 3 2 – 3 –
criteria (B) – 1 3 – ni
C. albicans
sample iii 1 – nd nd nd
sample iV nd nd nd nd nd
criteria (a) – – 2 – ni
Abbreviations: nd, not detectable; ni, no increase.
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In summary, anti-inflammatory ophthalmic products 
containing PR with enhanced bioavailability were formulated 
in aqueous solutions by means of CD inclusion complex 
formation with optimal mucoadhesion and antimicrobial 
properties. Although further experiments such as toxicity and 
permeation studies are needed, these results are promising for 
the formulation of innovative eye drops with high therapeutic 
effect and sufficient patient compliance.
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